These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 36274045)

  • 1. Changes in exercise endurance and inspiratory capacity after lumacaftor/ivacaftor therapy in cystic fibrosis.
    Savi D; Gramegna A; Vicenzi M; Di Paolo M; Messore B; Palange P; Blasi F
    Pulmonology; 2023; 29(4):338-341. PubMed ID: 36274045
    [No Abstract]   [Full Text] [Related]  

  • 2. Response to: 'Lumacaftor/ivacaftor for patients homozygous for Phe508del-CFTR: should we curb our enthusiasm?' by Jones and Barry.
    Elborn JS; Ramsey B; Wainwright C; Boyle M
    Thorax; 2016 Feb; 71(2):185-6. PubMed ID: 26506855
    [No Abstract]   [Full Text] [Related]  

  • 3. Lumacaftor/ivacaftor for patients homozygous for Phe508del-CFTR: should we curb our enthusiasm?
    Jones AM; Barry PJ
    Thorax; 2015 Jul; 70(7):615-6. PubMed ID: 26071414
    [No Abstract]   [Full Text] [Related]  

  • 4. Successful Pregnancy of a Patient with Cystic Fibrosis Genotype F508del/ F508del and Progressed Pulmonary Destruction on lumacaftor/ivacaftor.
    Mainz JG; Michl RK; Beiersdorf N; Lorenz M; Schneider U; Groten T; Jaudszus A
    Klin Padiatr; 2019 Sep; 231(5):271-273. PubMed ID: 31408905
    [No Abstract]   [Full Text] [Related]  

  • 5. Ivacaftor, not ivacaftor/lumacaftor, associated with lower pulmonary inflammation in preschool cystic fibrosis.
    Shanthikumar S; Ranganathan S; Neeland MR
    Pediatr Pulmonol; 2022 Oct; 57(10):2549-2552. PubMed ID: 35791043
    [No Abstract]   [Full Text] [Related]  

  • 6. Lumacaftor/ivacaftor (Orkambi) for cystic fibrosis.
    Med Lett Drugs Ther; 2016 Mar; 58(1491):41-2. PubMed ID: 27027688
    [No Abstract]   [Full Text] [Related]  

  • 7. A Review on the Use of Cystic Fibrosis Transmembrane Conductance Regulator Gene Modulators in Pediatric Patients.
    Bitonti M; Fritts L; So TY
    J Pediatr Health Care; 2019; 33(3):356-364. PubMed ID: 31029283
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lumacaftor/ivacaftor combination therapy for cystic fibrosis: A nationwide survey among clinicians.
    Casciaro R; Costa S; Dang P; Majo F; Ros M
    Clin Respir J; 2018 Apr; 12(4):1767-1768. PubMed ID: 28759146
    [No Abstract]   [Full Text] [Related]  

  • 9. Change in exercise capacity measured by Cardio-pulmonary Exercise Testing (CPET) in Danish people with cystic fibrosis after initiation of treatment with Lumacaftor/Ivacaftor and Tezacaftor/Ivacaftor.
    Rysgaard UK; Pedersen CL; Jensen JH; Sørensen L; Philipsen LKD; Leo-Hansen C; Olesen HV
    J Cyst Fibros; 2022 Sep; 21(5):844-849. PubMed ID: 35667973
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A new era in the treatment of cystic fibrosis.
    Lane MA; Doe SJ
    Clin Med (Lond); 2014 Feb; 14(1):76-8. PubMed ID: 24532752
    [No Abstract]   [Full Text] [Related]  

  • 11. Continuous glucose monitoring in youth with cystic fibrosis treated with lumacaftor-ivacaftor.
    Li A; Vigers T; Pyle L; Zemanick E; Nadeau K; Sagel SD; Chan CL
    J Cyst Fibros; 2019 Jan; 18(1):144-149. PubMed ID: 30104123
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treating Specific Variants Causing Cystic Fibrosis.
    Cutting GR
    JAMA; 2017 Dec; 318(21):2130-2131. PubMed ID: 29209709
    [No Abstract]   [Full Text] [Related]  

  • 13. Cystic fibrosis transmembrane conductance regulator modulators: precision medicine in cystic fibrosis.
    Burgener EB; Moss RB
    Curr Opin Pediatr; 2018 Jun; 30(3):372-377. PubMed ID: 29538046
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A combination therapy for cystic fibrosis.
    Brodsky JL; Frizzell RA
    Cell; 2015 Sep; 163(1):17. PubMed ID: 26406363
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of Organoid Swelling and
    Graeber SY; van Mourik P; Vonk AM; Kruisselbrink E; Hirtz S; van der Ent CK; Mall MA; Beekman JM
    Am J Respir Crit Care Med; 2020 Dec; 202(11):1589-1592. PubMed ID: 32687398
    [No Abstract]   [Full Text] [Related]  

  • 16. [Causal therapy is available].
    Meißner T
    MMW Fortschr Med; 2016 Jun; 158(12):74. PubMed ID: 27324018
    [No Abstract]   [Full Text] [Related]  

  • 17. A systematic Cochrane Review of correctors (specific therapies for class II CFTR mutations) for cystic fibrosis.
    Southern KW; Patel S; Sinha IP; Nevitt SJ
    Paediatr Respir Rev; 2019 Apr; 30():25-26. PubMed ID: 31128877
    [No Abstract]   [Full Text] [Related]  

  • 18. Cystic fibrosis transmembrane conductance regulator-modifying medications: the future of cystic fibrosis treatment.
    Pettit RS
    Ann Pharmacother; 2012; 46(7-8):1065-75. PubMed ID: 22739718
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of CFTR-modulating drugs on GH-IGF-1 axis impairment in adult patients with cystic fibrosis.
    Pascucci C; De Biase RV; Savi D; Quattrucci S; Gnessi L; Lubrano C; Lenzi A
    J Endocrinol Invest; 2019 Nov; 42(11):1361-1363. PubMed ID: 31006073
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cystic Fibrosis: The Dawn of a New Therapeutic Era.
    Heltshe SL; Cogen J; Ramos KJ; Goss CH
    Am J Respir Crit Care Med; 2017 Apr; 195(8):979-984. PubMed ID: 27710011
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.